Detalle Publicación

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Autores: González Martín, Antonio; Lluch, A.; Aba, E.; Albanell, J.; Anton, A.; Alvarez, I.; Ayala, F.; Barnadas, A.; Calvo, L.; Ciruelos, E.; Cortes, J.; de la Haba, J.; Lopez-Vega, J. M.; Martínez, E.; Muñoz, M.; Pelaez, I.; Redondo, A.; Rodríguez, A.; Rodriguez, C. A.; Ruiz, A.; Llombart, A.
Título de la revista: CLINICAL & TRANSLATIONAL ONCOLOGY
ISSN: 1699-3055
Volumen: 19
Número: 5
Páginas: 616-624
Fecha de publicación: 2017
Resumen:
High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.
DOI: https://doi.org/10.1007/s12094-016-1571-4
Impacto:
3 citas en
Google Scholar